KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Biomarin Pharmaceutical (BMRN) Shares Outstanding (Weighted Average) (2016 - 2025)

Historic Shares Outstanding (Weighted Average) for Biomarin Pharmaceutical (BMRN) over the last 17 years, with Q3 2025 value amounting to $192.0 million.

  • Biomarin Pharmaceutical's Shares Outstanding (Weighted Average) rose 84.18% to $192.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was $192.0 million, marking a year-over-year increase of 84.18%. This contributed to the annual value of $190.0 million for FY2024, which is 116.75% up from last year.
  • Per Biomarin Pharmaceutical's latest filing, its Shares Outstanding (Weighted Average) stood at $192.0 million for Q3 2025, which was up 84.18% from $191.9 million recorded in Q2 2025.
  • In the past 5 years, Biomarin Pharmaceutical's Shares Outstanding (Weighted Average) registered a high of $192.0 million during Q3 2025, and its lowest value of $181.8 million during Q1 2021.
  • Its 5-year average for Shares Outstanding (Weighted Average) is $187.1 million, with a median of $187.8 million in 2023.
  • As far as peak fluctuations go, Biomarin Pharmaceutical's Shares Outstanding (Weighted Average) soared by 145.5% in 2023, and later skyrocketed by 84.18% in 2025.
  • Over the past 5 years, Biomarin Pharmaceutical's Shares Outstanding (Weighted Average) (Quarter) stood at $182.9 million in 2021, then increased by 1.32% to $185.3 million in 2022, then rose by 1.39% to $187.8 million in 2023, then rose by 1.17% to $190.0 million in 2024, then grew by 1.06% to $192.0 million in 2025.
  • Its last three reported values are $192.0 million in Q3 2025, $191.9 million for Q2 2025, and $191.0 million during Q1 2025.